Commercialization Opportunities 

WBI is actively pursuing strategic alliances with other device companies to commercialize several of its technologies that are at an advanced stage of development. These include: transcutaneous energy transmission (TET) systems, drug-releasing materials for catheters, and a fibrin-based  topical hemostatic agent/tissue adhesive.

New Federal Awards

The company is pleased to announce the award of two new Small Business Innovative Research (SBIR) grants from the National Institutes of Health (NIH).

The first is a program to develop a new negative pressure ventilator that will significantly reduce the incidence of infection associated with long-term respiratory support. That program will be conducted with clinical investigators at the Massachusetts General Hospital in Boston.

The second is a progarm to develop new technology for monitoring the inlet pressure of implanted left ventricular assist devices. This is of particular importance for the rotary blood pump systems that have now entered clinical trials. Control of the pump speed to prevent generation of high negative pressures in the heart that can cause excessive blood damage or strokes remains a significant issue. Currently, these devices rely on mathematical algorithms that can only approximate conditions at the pump inflow.

Private Initiatives  

The company is seeking individual or group investors who are interested in the medical device sector. An immediate goal is to raise funds for commercializing the drug eluting urinary catheter we are developing to reduce the incidence of catheter-related urinary tract infection. The manufacturing will be done by our wholly owned subsidiary Cambridge Cardiovascular Incorporated.